TITLE

Advisory Panel Rejects Avastin for Breast Cancer Treatment

AUTHOR(S)
Koroneos, George
PUB. DATE
August 2010
SOURCE
Pharmaceutical Executive;Aug2010, Vol. 30 Issue 8, p13
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the decision of the U.S. Food and Drug Administration to discontinue the use of Avastin or bevacizumab as a treatment for breast cancer due to reports on inefficacy.
ACCESSION #
52978224

 

Related Articles

  • FDA extends review period of bevacizumab for treatment of advanced HER-2-negative breast cancer.  // Hem/Onc Today;10/10/2010, Vol. 11 Issue 19, p22 

    This article reports on the extension by the U.S. Food and Drug Administration (FDA) of the review period for the supplemental biologics license applications of bevacizumab for the treatment of previously untreated advanced HER-2-negative breast cancer.

  • FDA APPROVES AVASTIN FOR THE MOST COMMON KIDNEY CANCER.  // Biotech Business;Sep2009, Vol. 22 Issue 9, p7 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of Genentech Inc.'s Avastin plus interferon-alfa for people with metastatic renal cell carcinoma. According to executive vice president Hal Barron, Avastin has been approved to treat different types of cancer....

  • FDA actions in brief.  // Formulary;Jun2009, Vol. 44 Issue 6, p165 

    The article offers news briefs related to drug approvals given by the U.S. Food & Drug Administration (FDA). Avastin, a bevacizumab, has been approved for use as a single agent for the treatment of patients with progressive glioblastoma. A combination of amlodipine, valsartan, and...

  • How Much Is it Worth? Friedman, Joseph H. // Medicine & Health Rhode Island;Mar2012, Vol. 95 Issue 3, p70 

    In this article, the author presents his views on medical treatment breakthroughs and hike in prices of drugs in the U.S. He considers the U.S. Food and Drug Administration's (FDA) disapproval of avastin for metastatic breast cancer as biased and says that the disapproval indicates less...

  • FDA Actions.  // Neurology Alert;Apr2008, Vol. 26 Issue 8, p2 

    The article presents updates on the actions taken by the U.S. Food and Drug Administration (FDA) on some drugs. It has approved bevacizumab or Avastin for first-line treatment of women with metastatic HER2-negative breast cancer. An early communication has been also issued about an ongoing...

  • FDA Actions. Elliott, William T. // Primary Care Reports;Apr2008, Vol. 14 Issue 4, p2 

    The article announces the U.S. Food and Drug Administration (FDA) approval of bevacizumab (Avastin) for the treatment of metastatic HER2-negative breast cancer when used in combination with paclitaxel reducing disease progression compared to treatment with paclitaxel alone. The article also...

  • FDA Actions. Elliott, William T. // Clinical Oncology Alert;Apr2008, Vol. 24 Issue 4, p2 

    The article presents updates on the actions taken by the U.S. Food and Drug Administration (FDA) on some drugs. It has approved bevacizumab or Avastin for first-line treatment of women with metastatic HER2-negative breast cancer. An early communication has been also issued about an ongoing...

  • Erythropoietin and Cancer Death Rates. Elliot, William T. // Clinical Oncology Alert;Apr2008 Pharmacology Watch, p1 

    This section offers news briefs related to pharmacology. A meta-analysis found that erythropoiesis-stimulating agents (ESA) may increase the risk of death in cancer patients. A study by researchers from Georgetown examined preoperative triiodothyronine (T3) levels among a number of euthyroid...

  • FDA Actions.  // Infectious Disease Alert;Apr2008, Vol. 27 Issue 7, p2 

    The article presents updates on the actions taken by the U.S. Food and Drug Administration (FDA) on some drugs. It has approved bevacizumab or Avastin for first-line treatment of women with metastatic HER2-negative breast cancer. An early communication has been also issued about an ongoing...

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics